Pembrolizumab

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

Retrieved on: 
Tuesday, March 5, 2024
MRK, Hospital, News, FOLFIRINOX, Growth, AbbVie, PR, Neutrophil, Poster, Diagnosis, Pancreatic cancer, HBV, Incidence, Cancer, TME, Hepatology, Interleukin, Therapy, Prostate cancer, Liver, Immune system, Partnership, Merck & Co., AIO, PSMA, Inflammation, Safety, TILS, GPCR, Tumor microenvironment, Research, Medication, PALM, ABBV, Merck, Macrophage, Blood, FDA, TSX, Food, Ageing, Pembrolizumab, Pancreatic Cancer Action Network, Government, Prevalence, Ocean Biomedical, LAVA, PDAC, Patient, MHRA, Disease, ONC, PEI, Pharmaceutical industry

Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.

Key Points: 
  • Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.
  • The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers.
  • A report from Fortune Business Insights said that: “the pancreatic cancer treatment market size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029.
  • Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Retrieved on: 
Thursday, February 29, 2024
Head, Immunotherapy, Pembrolizumab, Stanford University, Patient, HNSCC, Pharmaceutical industry

The symposium is being held in Phoenix, Arizona and virtually from February 29 – March 2, 2024.

Key Points: 
  • The symposium is being held in Phoenix, Arizona and virtually from February 29 – March 2, 2024.
  • Dr. Colevas will discuss previously presented data from the company’s ongoing Phase 1 trial evaluating CUE-101, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma (HNSCC).
  • Poster Title: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic (R/M) HPV16+ head and neck cancer patients.
  • Presenter: Alexander Dimitrios Colevas, M.D., professor of medicine and medical oncologist, Stanford Cancer Center, Stanford University School of Medicine

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, February 29, 2024
Senior, Merck, Research, FDA, Food, Cancer, Pembrolizumab, AACR, Conference, Mirati, Science, Therapy, Food and Drug Administration, Merck & Co., Patient, Pharming, Clinical trial, Mutation, Workforce, Pharmaceutical industry

Promoted Michael Carulli to Chief Financial Officer and appointed Masha Poyurovsky, Ph.D., as Vice President of Biology.

Key Points: 
  • Promoted Michael Carulli to Chief Financial Officer and appointed Masha Poyurovsky, Ph.D., as Vice President of Biology.
  • As of December 31, 2023, PMV Pharma had $228.6 million in cash, cash equivalents, and marketable securities, compared to $243.5 million at December 31, 2022.
  • Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 31, 2022.
  • KEYTRUDA (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Retrieved on: 
Wednesday, February 28, 2024
Merck, ASCO, SITC, IPhone XR, Drug development, Pembrolizumab, Nature, Annual general meeting, IPR, Society, Therapy, Adenosine, Patient, D&O, Clinical trial, Immunotherapy, G&A, PRTG, Research, Fiscal, Life insurance

WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.

Key Points: 
  • WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.
  • R&D costs increased slightly by approximately $0.1 million, or approximately 1%, from approximately $2.7 million in the Fiscal 2023 Quarter, to approximately $2.8 million in the Fiscal 2024 Quarter.
  • G&A expenses decreased by approximately $0.7 million, or approximately 35%, from approximately $2.0 million in the Fiscal 2023 Quarter, to approximately $1.3 million in the Fiscal 2024 Quarter.
  • The Company’s other pre-tax items of income and expense were substantially non-cash in nature and aggregated to approximately $44.9 million net expense in the Fiscal 2024 Quarter, compared to approximately $0.6 million net expense during the Fiscal 2023 Quarter.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024
Cetuximab, Research, Castration, PRS, Intellectual property, Patient, Pancreatic cancer, HNSCC, EAP, Eli Lilly and Company, CRPC, Drug design, BLA, FTD, HER2, MET, Congress, Afatinib, Partnership, NSCLC, CD3, EGFR, ESMO, BTD, Betta, CRC, AACR, Safety, Biomarker, RECIST, Clinical trial, Oncology, Prostate cancer, Neoplasm, FDA, Pembrolizumab, Lung, Disease, Travel, Pharmaceutical industry

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Retrieved on: 
Thursday, February 22, 2024
Allotransplantation, Skin cancer, Cholangiocarcinoma, Fast track (FDA), NHL, Melanoma, FDA, Pembrolizumab, CD19, Rupture, Lung, Epidemiology, Breast, Safety, Neoplasm, ASX, Bone marrow, Patient, RECIST, MAST, National library, IMU, Blinatumomab, DLBCL, Cancer, BTC, Vaccine

Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.

Key Points: 
  • Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.
  • Notably, in our Phase 1 MAST CF33 oncolytic virus trial, we’ve seen encouraging response rates during dose escalation, including one complete response in a patient with cholangiocarcinoma, and two partial responses in melanoma as we continue to dose escalate with no safety issues.
  • Importantly, two out of three of these responses were achieved with CF33 monotherapy.
  • onCARlytics uses an antigen/target-armed CF33, followed by treatment with a CD19 targeting therapy directed against that antigen or target.

CEL-SCI Corporation Issues Letter to Shareholders

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Head, Neck, EMA, Health Canada, ESMO, Condition, Neoadjuvant therapy, Plasma protein binding, Neoplasm, Immunotherapy, Physician, Marketing, SCCHN, FDA, Food, BLA, Letter, Risk, European, Patent, COVID, Patient, Policy, MHRA, NOCC, United, Survival, Congress, NIHR, Diagnosis, Pembrolizumab, CGMP, PD-L1, Radiation, Pharmaceutical industry

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.
  • This letter will be sent to the Company’s shareholders along with the proxy to the upcoming annual meeting.
  • In October 2023, the new data were presented at the 2023 European Society for Medical Oncology (ESMO) Congress.
  • These features make it easy to write a label for Multikine, which is essential for drug approval.

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

Retrieved on: 
Thursday, February 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, NSCLC, Acquisition, Breast cancer, Head, Recurrence, Boshoff, CREST, MBC, Encorafenib, Growth, HR, Spacecraft, PFE, Prostate, Metastasis, Pembrolizumab, Lung, ADC, Monoclonal antibody, Webcast, Patient, Lymphoma, Multiple myeloma, Brentuximab vedotin, PD-L1, Cancer, Fine chemical

A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .

Key Points: 
  • A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .
  • “With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • Pfizer’s Oncology portfolio is focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.
  • Please read full Prescribing Information , including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, General Health, Pharmaceutical, Health, Toxicity, Growth, Ovarian cancer, Radiopharmaceutical, Patient, Anal cancer, Bicycle, McKinsey & Company, Head, Cervical cancer, EV, Neoplasm, ATM, Therapy, Food and Drug Administration, TNBC, Net, Former, CMC, Thromboxane A2, Immune system, NSCLC, MUC, Peripheral neuropathy, SunOpta, Safety, Ovary, Participation, Knowledge, Novartis, Lazard, BRC, FDA, Cancer, Food, Pembrolizumab, Government, ADC, Brentuximab vedotin, CD137, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.
  • We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.
  • Validating the company’s Bicycle® Radio Conjugates (BRC™) pipeline and partner for success, with updates expected from its wholly owned BRC program by mid-2024.
  • Advancing the company’s Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) immune-oncology pipeline through innovative partnerships.